利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.05 秒)

    Pharmaceutical combination of everolimus with dactolisib
    1.
    发明授权
    Pharmaceutical combination of everolimus with dactolisib 有权

    公开(公告)号：US10576076B2

    公开(公告)日：2020-03-03

    申请号：US15575703

    申请日：2016-05-20

    申请人： David Glass ,  Joan Mannick ,  Leon Murphy

    发明人： David Glass ,  Joan Mannick ,  Leon Murphy

    IPC分类号： A61K31/4745 ,  A61K31/436

    摘要： The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto.

    Methods and compositions using Kloto-FGF23 fusion polypeptides
    4.
    发明授权
    Methods and compositions using Kloto-FGF23 fusion polypeptides 有权
    使用Kloto-FGF23融合多肽的方法和组合物

    公开(公告)号：US08932589B2

    公开(公告)日：2015-01-13

    申请号：US13796711

    申请日：2013-03-12

    申请人： David Glass ,  Shou-Ih Hu

    发明人： David Glass ,  Shou-Ih Hu

    IPC分类号： A61K38/18 ,  A61K39/395 ,  C07K14/50 ,  C07K16/00 ,  C12N1/21 ,  C12N5/10 ,  C12N15/12 ,  C12N15/63 ,  C12N9/42 ,  C12N9/00 ,  A61K38/00

    CPC分类号： C07K14/50 ,  A61K38/00 ,  C07K14/705 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/32 ,  C12N9/2445 ,  C12N9/93 ,  C12Y302/00 ,  C12Y302/01021 ,  C12Y602/01003

    摘要： The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.

    摘要翻译： 本发明涉及用于预防或治疗年龄相关病症或代谢紊乱的方法，试剂盒和组合物。 本发明的Klotho融合多肽至少包括Klotho蛋白或其活性片段。 在一个实施方案中，融合多肽包含Klotho多肽，FGF（例如FGF23）和（任选地）修饰的Fc片段。 例如，Fc片段可以降低与Fc-γ受体的结合并增加血清半衰期。 Klotho融合蛋白可用于治疗和预防各种年龄相关病症和代谢紊乱。 在另一个实施方案中，融合多肽包含FGF（例如FGF23）和修饰的Fc片段。